Menu
Search
|

Menu

Close
X

Evoke Pharma Inc EVOK.OQ (NASDAQ Stock Exchange Capital Market)

2.71 USD
-- (--)
As of Jun 20
chart
Previous Close 2.71
Open --
Volume --
3m Avg Volume 14,446
Today’s High --
Today’s Low --
52 Week High 4.09
52 Week Low 1.86
Shares Outstanding (mil) 15.39
Market Capitalization (mil) 55.71
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.129
FY17
-0.841
FY16
-1.270
FY15
-1.888
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
8.23
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-230.38
14.38
Return on Equity (TTM)
vs sector
-428.40
16.08

EXECUTIVE LEADERSHIP

Cam Garner
Chairman and Co Founder, Since
Salary: --
Bonus: --
David Gonyer
CEO, Founder, Director, Since 2007
Salary: $362,250.00
Bonus: $152,145.00
Matthew D'Onofrio
Executive Vice President, Chief Business Officer Treasurer, Secretary ,, Since 2010
Salary: $313,875.00
Bonus: $105,462.00
Marilyn Carlson
Chief Medical Officer, Since 2013
Salary: $285,000.00
Bonus: $71,820.00
Todd Brady
Director, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

420 Stevens Ave Ste 370
SOLANA BEACH   CA   92075-2081

Phone: +1858.3451494

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

SPONSORED STORIES